Lipicure CV 10mg/75mg Capsule is a combination medication containing Atorvastatin 10mg and Clopidogrel 75mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Atorvastatin, a statin class drug, functions by inhibiting HMG-CoA reductase, leading to decreased cholesterol synthesis in the liver, thereby reducing low-density lipoprotein cholesterol (LDL-C) levels and overall cardiovascular risk. Clopidogrel, an antiplatelet agent, irreversibly inhibits the P2Y12 component of ADP receptors on platelet surfaces, preventing platelet aggregation and reducing the risk of thrombotic events such as myocardial infarction and stroke. Lipicure CV is primarily prescribed for patients with a history of atherosclerotic cardiovascular disease, acute coronary syndrome, or those at high risk of thrombotic complications who require simultaneous lipid control and platelet inhibition. The combination capsule enhances patient compliance by reducing pill burden. It is essential to monitor liver function tests and platelet counts periodically during therapy. Caution is advised in patients with active bleeding, hepatic impairment, or hypersensitivity to either component. Concomitant use with other anticoagulants or certain CYP3A4 inhibitors should be carefully managed to avoid adverse interactions. Lipicure CV should be used under strict medical supervision to optimize therapeutic outcomes and minimize risks.